Switch theme
Sign up to access all valuation multiples
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
2020
3
Last FY Revenue n/a
Last FY EBITDA -$8.1M
$29.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Anebulo Pharmaceuticals achieved revenue of n/a and an EBITDA of -$8.1M.
Anebulo Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anebulo Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$8.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$9.0M | XXX | -$8.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$8.5M | XXX | -$8.2M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Anebulo Pharmaceuticals's stock price is $1.
Anebulo Pharmaceuticals has current market cap of $42.9M, and EV of $29.6M.
See Anebulo Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.6M | $42.9M | XXX | XXX | XXX | XXX | $-0.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Anebulo Pharmaceuticals has market cap of $42.9M and EV of $29.6M.
Anebulo Pharmaceuticals's trades at n/a EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate Anebulo Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anebulo Pharmaceuticals has a P/E ratio of -5.1x.
See valuation multiples for Anebulo Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $42.9M | XXX | $42.9M | XXX | XXX | XXX |
| EV (current) | $29.6M | XXX | $29.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -3.3x | XXX | -3.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.1x | XXX | -5.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnebulo Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.8M for the same period.
Anebulo Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anebulo Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Anebulo Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anebulo Pharmaceuticals acquired XXX companies to date.
Last acquisition by Anebulo Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Anebulo Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Anebulo Pharmaceuticals founded? | Anebulo Pharmaceuticals was founded in 2020. |
| Where is Anebulo Pharmaceuticals headquartered? | Anebulo Pharmaceuticals is headquartered in United States of America. |
| How many employees does Anebulo Pharmaceuticals have? | As of today, Anebulo Pharmaceuticals has 3 employees. |
| Who is the CEO of Anebulo Pharmaceuticals? | Anebulo Pharmaceuticals's CEO is Mr. Richard Anthony Cunningham. |
| Is Anebulo Pharmaceuticals publicy listed? | Yes, Anebulo Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Anebulo Pharmaceuticals? | Anebulo Pharmaceuticals trades under ANEB ticker. |
| When did Anebulo Pharmaceuticals go public? | Anebulo Pharmaceuticals went public in 2021. |
| Who are competitors of Anebulo Pharmaceuticals? | Similar companies to Anebulo Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Anebulo Pharmaceuticals? | Anebulo Pharmaceuticals's current market cap is $42.9M |
| Is Anebulo Pharmaceuticals profitable? | Yes, Anebulo Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
